Developer docs
API playgroundTry for free, no card

Search company profiles

Novel Microdevices

Full company profile

uuid0000cy1

Namestring
Novel Microdevices
Legal namestring
Novel Microdevices, Inc.
Websiteurl
noveldx.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Novel Microdevices, Inc. (operating as Novel DX / Novel Dx) is a privately held, woman-owned medical device company founded in 2015 in Baltimore, Maryland by CEO Andrea Pais and VP of Engineering Rohan Pais. The company is developing a portable, battery-powered, under-4-pound point-of-care molecular diagnostic system that performs RT-PCR and isothermal Nucleic Acid Amplification Tests (NAAT) on disposable microfluidic cartridges, delivering lab-quality results in approximately 15 minutes. The product targets women's health, under-resourced populations, and infectious disease diagnostics in clinical and low-resource settings, with an assay menu that includes multiplex respiratory pathogens (RSV, Influenza A/B, COVID-19) and sexually transmitted infections including Chlamydia trachomatis, Neisseria gonorrhoeae, and antibiotic-resistant gonorrhea strains. The platform is designed for CLIA waiver eligibility, enabling use outside traditional laboratories.

The company's revenue model centers on sales of the Novel Dx instrument and proprietary disposable assay cartridges, with planned direct enterprise sales to healthcare providers, hospitals, clinics, and point-of-care settings. As of the most recent company materials, the Novel Dx System and Diagnostic Assays are explicitly stated as "in development and not available for sale," placing the company in a pre-commercial stage. The company has funded operations almost entirely through non-dilutive grants and awards, including up to $13.8 million from CARB-X (2021), $1.4 million Phase 1 and $2.68 million follow-on from NIH RADx Tech (2023 and 2024), $500,000 from TEDCO (2025), and $633,757 from the Maryland Department of Commerce Build Our Future Grant (2025) to establish a GMP-compliant pilot manufacturing facility at the Baltimore headquarters. The device is also cloud-connected (Novel Dx Cloud) with a customer portal (My Novel DX), and is positioned as stackable for throughput scaling in clinical workflows.

Short descriptiontext

Novel Microdevices is a Baltimore-based medical device company developing a portable, battery-powered point-of-care RT-PCR molecular diagnostic system (Novel Dx) that delivers lab-quality results in approximately 15 minutes on disposable microfluidic cartridges, targeting infectious disease testing — including respiratory pathogens and sexually transmitted infections — for women's health, underserved, and low-resource settings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBaltimore, United States
HQ citystring
Baltimore
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, molecular diagnostic devices, RT-PCR testing, microfluidic cartridges, infectious disease detection
Industry4 codes
PRIMARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Point-of-Care Molecular Diagnostics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Novel Dx Diagnostic System Sales
TypeHardware Sales
Description

The company generates revenue from sales of its Novel Dx point-of-care RT-PCR diagnostic device and associated disposable cartridges. The system detects respiratory viruses and STIs in approximately 15 minutes at the point of care.

noveldx.com
2Molecular Diagnostic Assays
TypeHardware Sales
Description

Revenue from proprietary assay tests for infectious disease detection including respiratory infections (Flu, RSV, COVID-19) and sexually transmitted infections (STIs).

noveldx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Novel Dx System
Description

A portable, battery-powered, point-of-care RT-PCR diagnostic platform that provides lab-quality results in under 15 minutes.

noveldx.com
+1 more record
Core offering1 text field

Novel Microdevices develops and is commercializing the Novel Dx system, a portable, battery-powered point-of-care RT-PCR molecular diagnostic platform weighing under 4 pounds. The system uses disposable microfluidic cartridges to perform automated sample-to-answer nucleic acid amplification testing, delivering lab-quality results in under 15 minutes for respiratory infections (Flu, RSV, COVID-19) and sexually transmitted infections including antibiotic-resistant gonorrhea.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 15-minute time-to-result vs. days for traditional lab testing
+3 more records
Product overview1 text field

Novel Microdevices commercializes Novel Dx, a proprietary point-of-care rapid molecular diagnostics system consisting of a portable hardware device (Novel Dx System) and disposable diagnostic assay cartridges. The system uses RT-PCR technology on microfluidic cartridges to deliver lab-quality results in under 15 minutes at the point of care. The product portfolio includes multiplex respiratory infection assays (Flu, RSV, COVID-19) and sexually transmitted infection tests (STIs), with the STI test specifically targeting antibiotic-resistant pathogens. The system is designed for portability (under 4 lbs, battery-powered), enabling use in low-resource settings and low-and middle-income countries.

Product and service2 records
1Novel Dx System
CategoryDiagnostic Hardware Device
Description

Portable, battery-powered point-of-care RT-PCR diagnostic platform weighing under 4 pounds, designed for CLIA waiver to enable use outside traditional laboratory settings. Runs disposable microfluidic cartridges that automate sample lysis, nucleic acid extraction, and PCR amplification for infectious disease detection.

2Novel Dx Respiratory Diagnostic Assays
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers3 records
1Abbott (ID NOW)
TypeBroad incumbent
TypeBroad incumbent
Description

Cepheid's GeneXpert system is the established point-of-care RT-PCR platform with CLIA-waived Xpress assays (e.g., Xpress Flu/RSV, Xpress CT/NG, Xpress SARS-CoV-2). Most directly comparable on multiplexing, time-to-result (~30 min for Xpress), and menu breadth, and dominates the POC molecular space Novel Microdevices is targeting.

TypeBroad incumbent
Description

BioFire FilmArray platforms (including the CLIA-waived SpotFire) deliver multiplex PCR results in ~15-20 minutes at the point of care. Directly comparable on platform architecture, time-to-result, and respiratory / STI panel strategy; BioFire is a leading incumbent in hospital POC molecular diagnostics.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Novel Microdevices

Point-of-Care Molecular Diagnosticsnoveldx.com

Novel Microdevices is a Baltimore-based medical device company developing a portable, battery-powered point-of-care RT-PCR molecular diagnostic system (Novel Dx) that delivers lab-quality results in approximately 15 minutes on disposable microfluidic cartridges, targeting infectious disease testing — including respiratory pathogens and sexually transmitted infections — for women's health, underserved, and low-resource settings.

What Novel Microdevices does

Novel Microdevices, Inc. (operating as Novel DX / Novel Dx) is a privately held, woman-owned medical device company founded in 2015 in Baltimore, Maryland by CEO Andrea Pais and VP of Engineering Rohan Pais. The company is developing a portable, battery-powered, under-4-pound point-of-care molecular diagnostic system that performs RT-PCR and isothermal Nucleic Acid Amplification Tests (NAAT) on disposable microfluidic cartridges, delivering lab-quality results in approximately 15 minutes. The product targets women's health, under-resourced populations, and infectious disease diagnostics in clinical and low-resource settings, with an assay menu that includes multiplex respiratory pathogens (RSV, Influenza A/B, COVID-19) and sexually transmitted infections including Chlamydia trachomatis, Neisseria gonorrhoeae, and antibiotic-resistant gonorrhea strains. The platform is designed for CLIA waiver eligibility, enabling use outside traditional laboratories.

The company's revenue model centers on sales of the Novel Dx instrument and proprietary disposable assay cartridges, with planned direct enterprise sales to healthcare providers, hospitals, clinics, and point-of-care settings. As of the most recent company materials, the Novel Dx System and Diagnostic Assays are explicitly stated as "in development and not available for sale," placing the company in a pre-commercial stage. The company has funded operations almost entirely through non-dilutive grants and awards, including up to $13.8 million from CARB-X (2021), $1.4 million Phase 1 and $2.68 million follow-on from NIH RADx Tech (2023 and 2024), $500,000 from TEDCO (2025), and $633,757 from the Maryland Department of Commerce Build Our Future Grant (2025) to establish a GMP-compliant pilot manufacturing facility at the Baltimore headquarters. The device is also cloud-connected (Novel Dx Cloud) with a customer portal (My Novel DX), and is positioned as stackable for throughput scaling in clinical workflows.

Novel Microdevices firmographics

Firmographics
Name
Novel Microdevices
Legal name
Novel Microdevices, Inc.
Website
https://noveldx.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Novel Microdevices is a Baltimore-based medical device company developing a portable, battery-powered point-of-care RT-PCR molecular diagnostic system (Novel Dx) that delivers lab-quality results in approximately 15 minutes on disposable microfluidic cartridges, targeting infectious disease testing — including respiratory pathogens and sexually transmitted infections — for women's health, underserved, and low-resource settings.
Ownership category
akta.pro rank

Novel Microdevices industry classification

Industry
Product category
Point-of-Care Molecular Diagnostics
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Point-of-care diagnostics
  • Molecular diagnostic devices
  • RT-PCR testing
  • Microfluidic cartridges
  • Infectious disease detection

Where Novel Microdevices is headquartered

Location

Headquarters

HQ city
Baltimore
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Novel Microdevices business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Infrastructure

Revenue model

  1. Novel Dx Diagnostic System Sales: The company generates revenue from sales of its Novel Dx point-of-care RT-PCR diagnostic device and associated disposable cartridges. The system detects respiratory viruses and STIs in approximately 15 minutes at the point of care.
  2. Molecular Diagnostic Assays: Revenue from proprietary assay tests for infectious disease detection including respiratory infections (Flu, RSV, COVID-19) and sexually transmitted infections (STIs).

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Novel Microdevices product offering

Product offering

Core offering

Novel Microdevices develops and is commercializing the Novel Dx system, a portable, battery-powered point-of-care RT-PCR molecular diagnostic platform weighing under 4 pounds. The system uses disposable microfluidic cartridges to perform automated sample-to-answer nucleic acid amplification testing, delivering lab-quality results in under 15 minutes for respiratory infections (Flu, RSV, COVID-19) and sexually transmitted infections including antibiotic-resistant gonorrhea.

Product overview

Novel Microdevices commercializes Novel Dx, a proprietary point-of-care rapid molecular diagnostics system consisting of a portable hardware device (Novel Dx System) and disposable diagnostic assay cartridges. The system uses RT-PCR technology on microfluidic cartridges to deliver lab-quality results in under 15 minutes at the point of care. The product portfolio includes multiplex respiratory infection assays (Flu, RSV, COVID-19) and sexually transmitted infection tests (STIs), with the STI test specifically targeting antibiotic-resistant pathogens. The system is designed for portability (under 4 lbs, battery-powered), enabling use in low-resource settings and low-and middle-income countries.

Differentiator

Problem solved

Functional benefit

Brands

  • Novel Dx System: A portable, battery-powered, point-of-care RT-PCR diagnostic platform that provides lab-quality results in under 15 minutes.
  • My Novel DX

Products and services

  • Novel Dx System Portable, battery-powered point-of-care RT-PCR diagnostic platform weighing under 4 pounds, designed for CLIA waiver to enable use outside traditional laboratory settings. Runs disposable microfluidic cartridges that automate sample lysis, nucleic acid extraction, and PCR amplification for infectious disease detection.
  • Novel Dx Respiratory Diagnostic Assays

Quantifiable outcome

  • 15-minute time-to-result vs. days for traditional lab testing
  • +3 more outcomes

Companies that use Novel Microdevices

Customer profile

Segments3 records

Ideal customer profiles2 records

Novel Microdevices technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Novel Microdevices partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Novel Microdevices competitors and assessment

Company assessment

Broad incumbents

  • Abbott (ID NOW):
  • Cepheid (Danaher): Cepheid's GeneXpert system is the established point-of-care RT-PCR platform with CLIA-waived Xpress assays (e.g., Xpress Flu/RSV, Xpress CT/NG, Xpress SARS-CoV-2). Most directly comparable on multiplexing, time-to-result (~30 min for Xpress), and menu breadth, and dominates the POC molecular space Novel Microdevices is targeting.
  • bioMérieux (BioFire): BioFire FilmArray platforms (including the CLIA-waived SpotFire) deliver multiplex PCR results in ~15-20 minutes at the point of care. Directly comparable on platform architecture, time-to-result, and respiratory / STI panel strategy; BioFire is a leading incumbent in hospital POC molecular diagnostics.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Novel Microdevices social profiles

Digital presence

Novel Microdevices financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Novel Microdevices leadership team

Management profile

Number of profiles

Profiles4 records

Novel Microdevices funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Novel Microdevices M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novel Microdevices

What does Novel Microdevices do?

Novel Microdevices develops and is commercializing the Novel Dx system, a portable, battery-powered point-of-care RT-PCR molecular diagnostic platform weighing under 4 pounds. The system uses disposable microfluidic cartridges to perform automated sample-to-answer nucleic acid amplification testing, delivering lab-quality results in under 15 minutes for respiratory infections (Flu, RSV, COVID-19) and sexually transmitted infections including antibiotic-resistant gonorrhea.

Is Novel Microdevices a public or private company?

Novel Microdevices is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Novel Microdevices founded?

Novel Microdevices was founded in 2015. It employs 11 to 50 people.

Where is Novel Microdevices based?

Novel Microdevices is headquartered in Baltimore, United States, in the North America region.

How does Novel Microdevices make money?

Two revenue lines are on record. Novel Dx Diagnostic System Sales are the primary driver. The others are molecular Diagnostic Assays.

Who are Novel Microdevices's main competitors?

Broad incumbents on record are Abbott (ID NOW), Cepheid (Danaher) and bioMérieux (BioFire).

Does Novel Microdevices have an API?

No public API is recorded for Novel Microdevices.

What industry is Novel Microdevices in?

Novel Microdevices's product category is Point-of-Care Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAN, Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics), with a secondary code of HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 334516 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TechnicalMaryland money brings significant upgrades to longtime Baltimore life sciences facilityBlackbird Laboratories and LaunchPort received state grants from Maryland to expand life sciences infrastructure at the City Garage facility in Baltimore. Blackbird Laboratories secured $2 million for a new incubator opening in 2026, while other tenants like Novel Microdevices and LaunchPort also obtained funding for manufacturing and R&D capabilities.NoveldxNovel DXNovel Microdevices, Inc. has been awarded a $633,757 grant by the Maryland Department of Commerce to establish a GMP-compliant pilot manufacturing facility in Baltimore. This funding supports the scaling of automated production for its rapid diagnostic platform, which delivers 15-minute PCR tests for infectious diseases at the point of care.citybizTEDCO Invests in Novel MicrodevicesTEDCO announced a $500,000 dual investment in Novel Microdevices, splitting $250,000 from Venture Funds and $250,000 from the Inclusion Fund. The company develops NovelDx, a rapid PCR test for point-of-care diagnostics. The investment aims to support continued development of the device.Maryland Entrepreneur Funding and InvestmentsTEDCO Invests in Novel MicrodevicesTEDCO announced a $500,000 dual investment in Novel Microdevices to support the development of its NovelDx point-of-care diagnostic device. The funding, split between TEDCO's Venture Funds and Inclusion Fund, aims to help the company bring rapid PCR testing technology to market.BiobuzzNovel Microdevices Secures $2.7 Million in Follow-On Funding from NIH RADx® Tech Program After Achieving Key MilestonesNovel Microdevices, Inc. of Baltimore, Maryland, announced on November 8, 2024 that it received $2.68 million in follow-on funding from the NIH RADx Tech program, following completion of performance milestones for its 15-minute multiplex RT-PCR platform. The company had received $1.4 million in Phase 1 funding in August 2023. CEO Andrea Pais said the non-dilutive award supports commercialization of the diagnostic.PrwebNovel Microdevices, Inc. Announces ~$2.7M Follow on Funding from NIH RADx® TechNovel Microdevices, Inc. received $2.68 million in follow-on funding from the NIH RADx Tech program after completing key performance milestones for its point-of-care RT-PCR platform. The platform detects RSV, influenza, and COVID-19 in 15 minutes. The company will use the funds to accelerate commercialization.Carb-XCARB-X is funding Novel Microdevices to develop a rapid and portable diagnostic for sexually transmitted diseases including antibiotic-resistant infectionsCARB-X awarded Baltimore-based Novel Microdevices up to $3.6 million in non-dilutive funding, with up to $10.2 million additional if milestones are met, to develop a rapid molecular test for sexually transmitted infections including Chlamydia and gonorrhea. The four-pound, battery-powered device reports results in about 25 minutes from a vaginal swab or urine sample and detects antibiotic-resistant bacteria. CARB-X is investing up to $480 million between 2016 and 2022.PrwebNovel Microdevices, Inc. Announces ~$1.4M Phase 1 funding from NIH RADx® TechNovel Microdevices, Inc. announced it has been awarded approximately $1.4 million in Phase 1 funding from the National Institutes of Health's RADx Tech program to support its rapid multiplex diagnostic platform. The award validates the company's technology for detecting RSV, influenza A and B, and COVID-19 in under 15 minutes, with potential for Phase 2 funding contingent on successful completion of this initial phase.SecSEC FORM DNovel Microdevices, Inc. filed a Form D with the SEC to report an exempt securities offering under Rule 506(b). The company has sold $4,375,000 of its $6,500,000 target amount to 29 investors since the first sale on February 10, 2021. The filing indicates the offering is intended to last less than one year and involves debt securities.